Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592886 | 0.88 | ESR1 (0.44) | SMN1; SMN2 | |
| SCHEMBL17873459 | 0.86 | RAB9A (0.52) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2817919 | 0.86 | LMNA (0.57) | ALDH1A1HPGDTP53MAPTLMNA | |
| SCHEMBL27521358 | 0.86 | HDAC1 (0.49) | SMN1; SMN2KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL13115988 | 0.85 | TARBP2 (0.52) | SMN1; SMN2KDM4EALDH1A1TP53MAPT | |
| SCHEMBL4902841 | 0.84 | MAPT (0.47) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL4907387 | 0.83 | PPARG (0.50) | KDM4EMAPTKMT2A | |
| SCHEMBL3590356 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL3578814 | 0.82 | FFAR1 (0.50) | SMN1; SMN2KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL3580916 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1HPGDTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1019378-B1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6541497-B1 | Amino acid derivatives of benzoxazin-2-ylaminoalkoxyphenylalkyl compounds | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6353027-B1 | ENANTIOMORPHIC AMINE DERIVATIVES FOR TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-1019378-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6194446-B1 | NON-INSULIN DEPENDENT DIABETES | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0925063-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6121282-A | 3-(CARBOXY, AMIDO, CYANO, OR HYDROXYAMINOCARBONYL)-6 OR 7-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1019378-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0925063-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000403-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5641796-A | PHENYL-OXAZOLYL-ALKYLOXY OR THIO-PHENYLALKYL TRIAZOLINE-3-ONE OR THIONE ANTIDIABETIC AGENT | ELI LILLY AND COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0177353-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4725610-A | TREATMENT OF HYPERLIPEMIA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0177353-A2 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | SMN1; SMN2 3894/4885KDM4E 4305/4885ALDH1A1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.